Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
UNC Lineberger Comprehensive Cancer Center
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03696784CT.gov Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03016377CT.gov Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL | — | Active Not Recruiting | — | — | — |
NCT03594162CT.gov Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Immunoproliferative Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ic9-car19 t cells (this asset) | UNC Lineberger Comprehensive Cancer Center | P1 | CC · 43 |
| Zilovertamab | Oncternal Therapeutics, Inc | P3 | B |
| Ibrutinib | Oncternal Therapeutics, Inc | P3 | B |
| Jcar-017 Cd19-Specific Chimeric Antigen Receptor | Juno Therapeutics, a Subsidiary of Celgene | P2 | B |
| Tucidinostat | Fudan University | P2 | CCC |
| Oricar-017 | OriCell Therapeutics Co., Ltd. | P1 | CC |
| Kln-1010 | Kelonia Therapeutics, Inc. | P1 | CC |
| Bendamustine | UNC Lineberger Comprehensive Cancer Center | P1 | CC |
| Fludarabine | UNC Lineberger Comprehensive Cancer Center | P1 | CC |
+4 more in the Immunoproliferative Disorder cohort
Other indications for ic9-car19 t cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Immune System Disorder | — | P1 | CC · 43 |
| Lymphatic System Disorder | — | P1 | CC · 43 |
| B-Cell Non-Hodgkin Lymphoma | — | P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. ic9-car19 t cells in Immunoproliferative Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ic9-car19-t-cells-immunoproliferative-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →